Start here if you're new
what it is
Ventas owns healthcare real estate, then collects rent from senior housing, medical offices, and research buildings.
how it gets paid
Last year Ventas made $5.8B in revenue.
why it's growing
Revenue grew 18.5% last year. Here, demand should be supported by a steadily increasing healthcare sector.
what just happened
Latest earnings cleared expectations, with EPS at $0.15 versus $0.11 expected.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
25/100 earnings predictability — expect surprises
157.4x trailing p/e — you're paying up for this one
2.5% dividend yield — cash in your pocket every quarter
3.5% return on capital — nothing to write home about
xvary composite: 42/100 — below average
What they do
Ventas owns healthcare real estate, then collects rent from senior housing, medical offices, and research buildings.
Ventas controls about 1,400 healthcare properties across the U.S., Canada, and the U.K. as of 12/31/24. Scale → lots of buildings under one platform → so what: you get tenant relationships and deal flow that smaller landlords cannot match. Its price stability score is 85 out of 100 while beta is 0.9, which means the stock has usually moved a bit less wildly than the market.
How they make money
$5.8B
annual revenue · their business grew +18.5% last year
total revenue
$5.8B
+18.5%
The products that matter
owns and operates senior housing
Senior Housing Portfolio
$5.8B revenue · +18.5% growth
this is the business. it produced $5.8B in revenue last year, and the 18.5% growth rate tells you occupancy and deal activity have both been moving in the right direction.
core engine
buys additional healthcare properties
Acquisition Pipeline
$2.0B+ invested in 2025
during the first nine months of 2025, ventas invested over $2.0B into senior housing acquisitions. that is not maintenance capital. that is the growth plan.
scale bet
Key numbers
157.4x
trailing p/e
P/E → how much you pay for each dollar of profit → so what: you are paying a huge price for a company that earned just $0.56 per share.
$5.8B
annual revenue
Revenue grew 18.5% vs. prior year, which tells you the properties are producing more cash even before earnings fully catch up.
2.5%
dividend yield
Yield → annual cash payout divided by stock price → so what: you are not buying Ventas for giant income today.
3.5%
return on capital
Return on capital → profit generated from the money used in the business → so what: Ventas is still squeezing modest returns from a huge asset base.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 85 / 100
- net profit margin 9.5% — keeps 10 cents of every dollar in revenue
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in VTR 3 years ago → it's now worth $18,880.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Latest earnings cleared expectations, with EPS at $0.15 versus $0.11 expected.
Quarterly EPS beat estimates by 36.36%. Revenue reached $4.3B, up 187% vs. prior year, while annual revenue was $5.8B, up 18.5% vs. prior year.
$4.3B
revenue
$0.40
eps
gross margin
the number that mattered
The key number was the 36.36% EPS beat, because Ventas needs steady proof that earnings are finally catching up to the stock price.
-
ventas’ business should continue to strengthen.
-
for the full year 2025, we think the top line will reach $5.8 billion, representing an impressive 18% annual advance.the dramatic improvement reflects the continued recovery of ventas’ senior housing portfolio, which suffered a setback during the coronavirus pandemic. moreover, we think demand for senior housing should be supported by an expanding elderly population. elsewhere, ventas’ medical office properties (outpatient centers and research facilities) should also post better results.
-
here, demand should be supported by a steadily increasing healthcare sector.
-
expansion plans are in place.during the first nine months of 2025, ventas invested over $2.0 billion into various senior housing acquisitions.
-
we also think the reit has actively pursued purchases in the final months of the year.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is senior housing recovery stalling after the acquisition wave.
med
occupancy and rent momentum cools off
ventas just grew revenue 18.5% to $5.8B. if senior housing demand softens, the rebound math that made the story look easy gets much harder.
with a 5.0% net margin, there is not a huge cushion if property-level performance slips.
med
$2.0B+ of acquisitions fail to earn their keep
during the first nine months of 2025, ventas invested over $2.0B into acquisitions. buying growth is fine. overpaying for it is expensive for a long time.
if those assets do not lift earnings above the recent $0.14 quarterly level, the market will question the whole expansion plan.
med
reit status complications would hit the model directly
this company is built to operate as a REIT. losing that status would change the tax structure and put pressure on capital returns.
that matters to shareholders collecting a 2.5% dividend and owning the stock for real-estate income characteristics.
Ventas is big enough to recover from a soft quarter. it is not big enough to ignore weak acquisition returns, thin 5.0% margins, or a slowdown in the senior housing rebound that just got revenue to $5.8B.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next quarterly print
the next update needs to show that the $1.5B revenue run rate was not a one-quarter spike.
risk
senior housing recovery
watch occupancy and pricing trends. 18.5% growth looks great until the comparison base catches up.
metric
acquisition returns
Ventas put $2.0B+ to work in 2025. you want to see those deals show up in earnings, not just in the property count.
trend
institutional flow
net buying lasted three straight quarters. if that reverses while the stock sits near the top of its range, pay attention.
Analyst rankings
short-term outlook
bottom 5%
momentum score 5 — the lowest rating. in human-speak, analysts think the next 12 months could disappoint even if the business keeps improving.
risk profile
average
stability score 3 means middle-of-the-pack risk. not a bunker stock, not chaos either.
chart momentum
average
technical score 3 says the chart is behaving normally. there is no screaming signal here.
earnings predictability
25 / 100
low predictability means quarterly results can swing around more than you want. that matters when the valuation already assumes progress.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 440 buyers vs. 303 sellers in 3q2025. total institutional holdings: 0.5B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$70
$129
$79
current price
$100
target midpoint · +27% from current · 3-5yr high: $100 (+25% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive